Thermo Fisher Scientific has introduced several new products that build on its leading Orbitrap platform and expand research applications. The new Thermo Scientific Orbitrap Exploris 240 mass spectrometer is designed to give scientists working in proteomics, metabolomics, biopharmaceutical characterisation and small-molecules, the analytical performance required for research and high-throughput analyses. The company says the new system will advance discovery and identification with increased accuracy for confident scale-up, while providing operational simplicity and streamlining time-to-result.
Thermo Fisher Scientific pointed out that the new mass spectrometer delivers qualitative and quantitative capabilities synonymous with Orbitrap high-resolution accurate-mass (HRAM) spectrometry, with internal calibration that assures consistent data quality and decision making. These newest systems extend the Thermo Scientific Orbitrap Exploris portfolio of HRAM systems, which were introduced in 2019 with the release of the new-generation Thermo Scientific Orbitrap Exploris 480 mass spectrometer.
Software
Thermo Scientific Proteome Discoverer 2.5 software provides high confidence during peptide identification, accurate quantification and high throughput data analysis for proteomics researchers. Deep learning-based prediction of tandem mass spectra, facilitated through a new collaboration with MSAID, a software company transforming proteomics through deep learning, enables more scientists to benefit from major improvements in identification confidence and reproducibility.
To further enhance characterisation of protein biotherapeutics and oligonucleotide therapeutics, biopharmaceutical laboratories use the Thermo Scientific BioPharma Finder 4.0 software, which provides greater flexibility and customisation for this growing industry.
For small molecule researchers, Thermo Scientific Compound Discoverer 3.2 software further automates unknown compound identification performed on Thermo Scientific Orbitrap Gas Chromatography- Mass Spectrometry (GC-MS) systems to improve productivity.
In addition, the new Thermo Scientific Xcalibur 4.4 software brings the AcquireX intelligent data acquisition workflow to Thermo Scientific Orbitrap Exploris mass spectrometry platform users, enabling the fully automated acquisition of high quality MS/MS data and reducing manual input and repeat runs.
Collaboration
Thermo Fisher Scientific’s collaboration with Evosep, a leading provider of sample preparation technologies for protein-based clinical research, supports the development of high-throughput clinical research workflows for profiling large plasma sample cohorts for proteomics, translational research and pharmaceutical applications. This partnership recently led to the launch of an automated ultra-high throughput plasma protein profiling platform, combing the power of the new Thermo Scientific Orbitrap Exploris 240 mass spectrometer with the Evosep One liquid chromatography solution.
The company’s collaboration with Biognosys, a leading developer of next-generation proteomics solutions, resulted in the development of data-independent acquisition mass spectrometrybased workflows, which enhances sensitivity and coverage for proteomic research in translational and clinical labs. The collaboration includes a novel FAIMS-DIA method that features the Thermo Scientific FAIMS Pro interface, which improves selectivity, reproducibility and proteome coverage, as well as new methods that streamline discovery by combining Thermo Scientific SureQuant Targeted Assay Kits and the Biognosys PQ500 kit in a single workflow.
For more information, visit: www.thermofisher.com
Read more

Hemco has introduced the CleanAire II Ductless Hoods, designed to meet DH I requirements as defined by SEFA 9. This hood features a built-in carbon filtration system to adsorb non-toxic fumes and odors. It is equipped with an integral blower, vapor proof light, fan and light switches.
The hood superstructure is constructed of chemical and flame resistant, non-metallic (no rust) composite resin with a molded one-piece seamless interior fume chamber. A vertical sliding clear acrylic sash protects the user and contains the process fumes. The carbon filter adsorbs the fumes and then re-circulates the air back to the laboratory.
The CleanAire II Ductless Hoods are available in 24”, 30”, 35”, and 47” models and are shipped completely assembled and ready for operation.
For more information, visit: www.hemcocorp.com/caii.html
Read more

Now available for Horiba Medical’s Yumizen G hemostasis range of instruments, the new Yumizen G DDi 2 (D-Dimer) reagent kit offers a key measurement and reference exclusion test for the diagnosis of deep vein thrombosis (DVT) and pulmonary embolism (PE). It can also be used for monitoring the progress and effectiveness of treatment of Disseminated Intravascular Coagulation (DIC). HORIBA Medical’s new D-Dimer reagent kit is available for its full range of coagulation instruments which covers the needs of any laboratory. The dedicated hemostasis portfolio includes the fully automatic Yumizen G800, Yumizen G1500 and Yumizen G1550, as well as semi-automatic Yumizen G200 and Yumizen G400 analysers. Using antibody-coated latex particles and measured via the immuno-turbidimetric channels of these Yumizen G instruments, the new reagent kit delivers D-Dimer results consistency across the range.  The D-Dimer assay when used on very compact coagulation screening platforms such as the Yumizen G400DDi and Yumizen G200, which also have combined immuno-turbidimetric and chromogenic assay capabilities, is particularly suitable for small laboratories, hot labs and as backup. On these semi-automatic systems, the Yumizen G DDi 2 reagent kit offers an innovative combination of immuno-turbidimetric test capability and pre-calibrated ready-to-use reagent. Offering a cost-efficient solution, the new assay minimizes preparation time due to its ready-to-use liquid format. Furthermore, as the reagent is pre-calibrated it removes the need for a costly and time-consuming calibration step. Its high stability and optimized volume packaging also avoid wastage. HORIBA Medical’s new D-Dimer test kit is fully compliant with Gold Standard performances, having a Negative Predictive Value of 99% and an absence of hook effect up to 25 µg FEU/ml. It also offers slope check and post dilution function on both fully automatic and semi-automatic systems with a cut-off value at 0.5 µg FEU/ml.

HORIBA MEDICAL
Read more

CE marking has been granted to one of the most comprehensive cartridge-based STI tests. The test, developed by the UK’s largest health diagnostics company, Randox Laboratories, tests simultaneously for 10 of the most common sexually transmitted infections, on the firm’s patented Biochip Technology. Quickly and efficiently testing for multiple STIs, which often have mild symptoms if any at all, ensures early diagnosis at a stage when treatment is most successful, supports the targeted use of antibiotics, and ultimately reduces their mishandling. Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented; “Antibiotic stewardship is a critical issue which we all have a responsibility to embrace and drive forward. The CE marking of the STI assay, which incorporates Randox Biochip Technology, will be a game-changer for clinicians and patients across Europe, by facilitating early, accurate and comprehensive diagnoses of STIs that allows for the best possible patient outcome. Never before has there been this level of accessibility and speed with regards to STI testing.”
The Randox STI assay is performed on the Vivalytic system, an intuitive point-of-care platform, developed in partnership with German technology company Bosch that provides the broadest range of test options ever seen for an analyser of its size. Harnessing the application of multiplex assays to provide greater information from a single patient sample, the Vivalytic simplifies the testing process for otherwise complex laboratory testing procedures.
Marc Meier, Managing Director of Bosch Healthcare Solutions, a subsidiary of Bosch Group, said: “We are enthusiastic about partnering with Randox to offer their assay technology on the Vivalytic platform. The core competencies of Bosch in automation, miniaturization, sensor technology and connectivity are complemented by Randox’s expertise in developing excellent biocontent for a wide range of assays and commercializing innovative diagnostic solutions.”
Read more